No, it would shorten the time frame of when we would hear of events. But that would be because there would be a larger patient pool (higher enrollment count) to which to reach 248 PFS events and 233 OS events. However, that is if they would have started screening months ago. At this point, I don't think screening more patients will help with the PFS endpoint. Too many months have gone by, and it is unlikely that any new enrolled patient would see a PFS event to contribute to the PFS endpoint. But as far as OS, considering many vaccine patients could live 3+ year, and only a smaller percentage do not, resuming enrollment may contribute to reaching the OS a couple of months sooner. It's all about the number of patients to derive events, and helping to cover for any lost to follow up patients. But on that point, this trial LTFU may end up being very low, and the 348 count may include that LTFU number, and if so, then they may not need the full 348 patient count anyway. Impossible for us to know. And that data point (percentage of LTFU patients) wouldn't have been known to the company until 12 months after all patients are enrolled. That might not be until October...
Market Data 
Markets 
AI
